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Abstract
Although anaesthesia itself is nowvery safe, perioperative cardiac complications during non-cardiovascular
surgery are a major cause of morbidity and mortality, because of the increasingly high underlying
prevalence of cardiovascular disease. Fortunately, although there is no “magic bullet”, pharmaco-
logical intervention can reduce the risk. In particular, current evidence strongly supports the use of
aspirin and statins. Beta blockers may also be beneficial in higher risk groups but need to be titrated
to effect, and their use requires careful consideration because of adverse effects in these patients.
Introduction
Despite better awareness of epidemiology and patho-
physiology, the worldwide prevalence of cardiovascular
disease is increasing. Contemporaneously, medical
advances are resulting in more patients with cardiovas-
cular comorbidity presenting for surgery. Although
anaesthesia itself is now very safe [1,2], perioperative
cardiac complications are a major cause of morbidity
and mortality as a consequence of the high underlying
prevalence of cardiovascular disease; for example, the
American Heart Association (AHA) estimates that more
than 2200 Americans die of cardiovascular disease each
day, an average of 1 death every 39 seconds [3].
Fortunately, there is evidence that pharmacological
intervention can reduce risk. This review will look at
the drugs available and their possible mechanisms in
modifying the pathophysiology of a perioperative acute
myocardial infarction. The roles of other interventions
such as prophylactic coronary revascularization, anaes-
thetic technique and cardiac conditioning are also
discussed.
Pathophysiology and risk stratification
The pathophysiology of perioperative myocardial infarc-
tion is more complex than in the non-surgical setting.
The metabolic responses to surgical stress and pain alter
physiology and trigger a cascade of biochemical events
that are prothrombotic. Moreover, myocardial oxygen
consumption is raised during the perioperative period,
which affects the oxygen supply/demand balance, and
intraluminal shear forces in the coronary artery can be
increased. This is a “perfect storm” for atheromatous
plaque rupture and subsequent coronary artery throm-
bosis. Many of these vulnerable plaques are asympto-
matic preoperatively and may not even be apparent with
angiography, as a result of positive remodelling within
the vessel [4,5].
Preoperative risk stratification aims to determine who is at
risk, optimize medical therapy and modify risk factors.
Unnecessary and costly cardiac testing should be avoided
if possible, as it can be potentially hazardous and often
has no impact on the perioperative management [6].
A number of guidelines and risk scores have been
developed to evaluate perioperative cardiac risk. For
instance, Lee’s Revised Cardiac Risk Index identifies six
independent variables that predicted an increased risk
for perioperative cardiac complications. These include
the following: (1) history of ischaemic heart disease;
(2) history of congestive heart failure; (3) history of
cerebrovascular disease; (4) diabetes mellitus; (5) chronic
renal impairment (creatinine>2 mg/dL); and (6) under-
going suprainguinal vascular, intraperitoneal, or
intrathoracic surgery [7]. This risk index is also incorpo-
rated into the AHA preoperative cardiac risk evaluation
guideline for non-cardiac surgery [8].
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Surgical coronary revascularization is a major under-
taking with significant morbidity and mortality itself.
Percutaneous coronary intervention with balloon angio-
plasty and stenting, while effective for the treatment of
angina, does not reduce the risk of perioperative
myocardial infarction, probably because it does not
treat all the atheromatous plaques present. Paradoxi-
cally, percutaneous coronary intervention actually
increases the risk of thrombosis by virtue of vessel
trauma and stent insertion. Patients will require dual
antiplatelet therapy with aspirin and clopidogrel, thereby
increasing bleeding during surgery [9,10]. This treatment
needs to be continued for three months with bare metal
and at least a year with drug eluting stents. Since surgery
in such patients is often not truly elective (e.g. cancer or
vascular surgery) the emphasis has shifted from coronary
revascularization to medical therapy in recent years.
Medical therapy is generally focused on improving
myocardial oxygen supply-demand balance and coron-
ary plaque stabilization. Data from large registries and
clinical trials indicate that drugs that have demonstrated
protective cardiovascular properties in the population of
patients treated medically may also confer benefits in
those treated surgically [6]. In addition to losing the
pharmacological benefits of a drug, discontinuation of
therapy (either perioperatively or otherwise) may cause a
rebound phenomenon. This has been demonstrated
with beta-blockers, aspirin, and statins. As a result, these
drugs should be continued throughout the perioperative
period or discontinued for the minimum period
possible.
Risk modulation
Aspirin
Aspirin has been used as an analgesic and anti-
inflammatory agent since 1897. Today, however, it is
most widely used as an antiplatelet agent. The drug
works on the cyclooxygenase enzyme system to irrever-
sibly inhibit platelet aggregation. It takes 5-7 days
to produce new platelets after cessation of therapy. In
primary coronary prevention, it is probable that the
anti-inflammatory properties of aspirin are also extre-
mely important [11,12].
As platelet aggregation predominates during the peri-
operative period, management of aspirin therapy is
imperative. While increased surgical bleeding is generally
evident, this is usually not clinically significant and
transfusion requirements have been found to be similar,
regardless of aspirin uptake [13]. In addition, there is an
approximate 2-3 fold increase in subsequent death or
myocardial infarction if aspirin is stopped prior to surgery
[14]. In patients with coronary stents in situ, it is strongly
advised to continue with aspirin, especially in the period
when in-stent thrombosis is prevalent and can cause a
5-30%mortality rate depending on how recently the stent
has been inserted [15-19]. Interestingly, this perioperative
cardioprotection effect is not apparent with other non-
steroidal anti-inflammatory drugs (NSAIDs) as they have a
different mechanism of action [20]. In fact, both NSAIDs
and cox-2-specific inhibitors have been associated with an
increased risk of perioperative myocardial infarction in
certain patients and procedures [21]. It is also important to
point out that aspirin protection cannot be substituted by
anticoagulant medication (e.g. low molecular weight
heparin often used for deep vein thrombosis [DVT]
prophylaxis) as they do not inhibit platelet function or
decrease inflammation.
Beta blockers
Beta adrenoreceptor antagonists are a particularly useful
class of drugs for the management of cardiac arrhyth-
mias, cardioprotection after myocardial infarction and
hypertension. They diminish the effects of epinephrine
and other stress hormones and have negative chrono-
tropic and inotropic actions. Beta blockers may also limit
activation of inflammatory responses including leuko-
cyte recruitment, metalloproteinase activity, monocyte
activation, growth factor release, and inflammatory
cytokine responses [22]. They protect the coronary
endothelium from damage by shearing forces and
turbulent flow, thus reducing atheroma formation and
plaque rupture. They reduce myocardial energy usage by
blunting catecholamine surges and reduce circulating
free fatty acids via inhibition of lipolysis, protecting
against ventricular fibrillation and sudden cardiac death.
Beta blockers also produce a shift of myocardial energy
usage from fatty acid oxidation towards glucose, which
further improves myocardial oxygenation and energy
efficiency, and they also reduce blood pressure via their
anti-renin/angiotensin properties [23].
There was widespread initial enthusiasm for the peri-
operative use of beta-blockers following the publication
of a number of relatively small but very compelling
studies, although there have since been some concerns
over the integrity of one of the authors. More recent and
larger trials with slightly different design, inclusion
criteria and also type and dose of beta blockers used
have dampened this. Among them, the largest multi-
centre randomized controlled trial is the POISE study
[24]. In POISE, extended-release metoprolol significantly
reduced myocardial infarction (4.2% vs 5.7%; p = .0017)
but increased stroke (1.0% vs 0.5%; p = .0053), thereby
resulting in a higher overall mortality (3.1% vs 2.3%;
p = .0317). Some limitations of POISE were that only the
outcomes of acute perioperative beta blockade were
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studied, the effect of withdrawal of beta blockers was
overlooked and the same dose was used in all patients
with no titration to effect.
A number of other studies have now shown a myocardial
benefit from perioperative beta blockade at the cost of
other harmful outcomes. The general consensus is that
high risk patients will benefit from beta blockers, but it is
apparent that a routine fixed regimen of therapy
perioperatively may be harmful in low/intermediate
risk groups. The variable response among patients may
be partially explained by genetic polymorphism and,
therefore, it seems prudent that individualised therapy
should be implemented when that becomes possible.
The type of beta blocker used might also have contributed
to different study outcomes. Although trials clearly
demonstrate cardioprotective effects, some evidence sug-
gests that those that are highly b1 selective show better
results than those that are moderately b1 selective. This
might explain why bisoprolol (highly b1 selective) has
been associated with better results, and metoprolol and
atenolol (moderately b1 selective) have been associated
with mixed results in clinical trials. In one large trial with
patients receiving perioperative beta blockers, longer
acting agents (e.g. atenolol) gave greater cardioprotection
than short-acting agents (e.g. metoprolol) [25]. Currently,
several guidelines recommend continuation of beta
blocker therapy in chronic treatment (e.g. the AHA have
this as a class I guideline indication [8]). The recommen-
dation to use beta blockers in patients undergoing vascular
surgery who are at high cardiac risk (e.g. those with
evidence of coronary artery disease, cardiac ischaemia on
preoperative testing) shifted from a class I to a class IIa
level of evidence and there are similar guidelines from the
European Society of Cardiology (ESC) [26]. High-, and
possibly intermediate-, risk individuals are likely to benefit
from beta blockers but careful titration of heart rate to
60 and 80 bpm and blood pressure response is suggested
[8]. Therapy should ideally start as soon as possible before
surgery (30 days to 1 week) but can still be considered
acutely. As yet, there are no guidelines on postoperative
duration of therapy, or whether it should be lifelong.
Statins
Statins are a class of drugs used to lower cholesterol
levels by inhibiting the enzyme HMG-CoA reductase,
which plays a central role in the production of
cholesterol in the liver. Although hypercholesterolaemia
is a risk factor for ischaemic heart disease, recent data
suggest that the cardioprotective effect of statins is also
related to their pleiotropic effects beyond low density
lipoprotein (LDL) lowering [27]. These include increased
endothelial nitric oxide synthetase with improved
endothelial function, improved thrombogenic profile,
anti-inflammation, and inhibition of artherosclerosis.
They have a very good safety profile. Rhabdomyolysis,
the most serious complication, is extremely rare and
about 2% of patients develop raised transaminases,
which are reversible on cessation of therapy.
A recent systematic review [28] and meta-analysis found
that perioperative statin treatment in statin-naive patients
reduces atrial fibrillation, myocardial infarction, and
duration of hospital stay. Several small prospective studies
introducing statins prior to high-risk vascular surgery have
shown a reduction in myocardial infarction, stroke and
death, irrespective of initial serum cholesterol level [29,30].
There is also an association with a reduced incidence of
contrast-induced nephropathy [31]. In view of the relative
safety and pharmacoeconomic benefits, it has even been
suggested that perioperative statin therapy for patients with
cardiac disease undergoing non-cardiac surgery may be the
most cost-effective use yet discovered [32].
Coronary artery interventions
Two randomized controlled trials have found absolutely
no postoperative or long-term benefit from percuta-
neous coronary intervention in high-risk patients under-
going major vascular surgery compared with the best
medical treatment alone. This reflects the inherent
complications of such procedures and the fact that
patients having coronary stents are at high risk of in-stent
thrombosis with high mortality, especially if antiplatelet
agents are stopped perioperatively. As for coronary artery
bypass surgery, it is suggested that only those who might
benefit from coronary artery bypass surgery independent
of their need for surgery should be considered.
Myocardial conditioning
Preconditioning is a form of myocardial protection that
delays the trespass of the ischaemic threshold by
lowering metabolic demand, and then secondarily
mitigating the adverse consequences of reperfusion as
the blood supply is restored. In 1986, Murry and
colleagues observed that intermittent ischaemia inten-
tionally applied to themyocardium actually improved its
ability to withstand subsequent ischaemia of greater
magnitude [33]. This adaptive phenomenon was termed
ischaemic preconditioning, but the mechanical nature of
its application rendered it cumbersome and time con-
suming, and, consequently, it was not adopted as routine
practice. However, the potential clinical implications of
this fascinating innate cardioprotective observation
inspired many researchers to examine the underlying
molecular mechanisms. It became apparent that certain
ligand-receptor interactions can activate similar pathways
and replicate the preconditioning response. Interestingly,
many of these preconditioning pharmacomimetics
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include drugs that are already in perioperative use such
as volatile anaesthetics and opioids. It was later observed
that mechanical ischaemia at the time of reperfusion
could also produce protection (postconditioning) and
this, also, could be induced by the same drugs
(pharmacologic postconditioning). Przyklenk and others
observed that an ischaemic stimulus applied to the
circumflex coronary artery protected the area of tissue
supplied by the left anterior descending coronary artery
and, from this observation, spawned the concept of
remote preconditioning [34]. The application of the
protective stimulus to an organ remote to the heart
became an attractive proposition as it avoids many of the
limitations of direct ischaemic preconditioning.
Although details of mechanisms of cardioprotection
continue to accumulate in the laboratory, translation to
the clinical setting has been disappointing. Part of the
reason is that diseased and senescent myocardium does
not behave like the normal myocardium of animals in
the laboratory. In addition, patients with coronary artery
disease may already be preconditioned with ischaemia
such that preconditioning drugs confer little additional
benefit, and most clinical studies have been in patients
undergoing cardiac surgery rather than those with cardiac
disease undergoing non-cardiac surgery.
Anaesthetic interventions
Certain volatile anaesthetic agents mimic some of the
biological effects of ischaemic preconditioning with
signal transduction pathways very similar to those
responsible for ischaemic preconditioning. It is hypothe-
sized that volatile anaesthetics stimulate a trigger that
initiates a cascade of events leading to activation of an
end-effector that is responsible for resistance to injury.
Adenosine type 1 (A1) receptors, protein kinase C (PKC),
inhibitory guanine nucleotide binding (Gi) proteins,
reactive oxygen species, and mitochondrial and sarco-
lemmal ATP-sensitive potassium channels have all been
implicated. There also appear to be important roles for
prosurvival kinases such as phosphoinositide 3-kinase
(PI3K)/Akt40 and the transcription factor HIF-1 [35].
Volatile anaesthetics also produce coronary vasodilation
by activating ATP-sensitive potassium channels or by
affecting intracellular Ca2+ homeostasis in vascular
smooth muscle. For example, sevoflurane can increase
collateral blood flow to ischaemic myocardium and
improve the functional recovery of coronary vascular
reactivity and nitric oxide release in isolated hearts after
global ischaemia [36]. Volatile anaesthetics may also
attenuate apoptosis after ischaemia/reperfusion and shift
the myocardium into an “anti-apoptotic” state by
modulation of proteins of the BCL-2 family. Conse-
quently, the use of volatile agents, particularly sevoflur-
ane, as a primary anaesthetic agent has undergone a
resurgence in popularity despite previous concerns over
their negative inotropic effects.
Opioid receptor activation can also confer cardiac
protection, in particular the delta and kappa receptor
subtypes. Intravenous morphine mimics the effects of
ischaemic preconditioning, albeit at high doses [37]. The
requirement for activation of delta and kappa receptors
by morphine may explain the relatively high doses
necessary to trigger cardioprotection (morphine being
predominantly a mu agonist). Such high morphine
doses would cause prolonged respiratory depression and
sedation and would be impractical for large scale clinical
use, so the advent of remifentanil, with its favourable
pharmacokinetic profile, enabled clinical trials of opioid
cardioprotection to be conducted. A meta-analysis of
remifentanil use in cardiac surgery of 1473 patients
showed that it is associated with a reduction in cardiac
troponin release, time of mechanical ventilation, and
length of hospital stay [38]. Remifentanil also attenuates
tachycardia, which improves the myocardial oxygen
supply/demand ratio in a similar way to beta blockers.
Reactive oxygen species have been implicated in
ischaemia/reperfusion injury. Propofol appears to be a
powerful antioxidant with effects similar to alpha-
tocopherol, which protects against cardiac ischaemia/
reperfusion injury mainly via enhancement of endogen-
ous antioxidant capacity in the myocardium [39]. This
mechanism is totally different from volatile anaesthetic
preconditioning. Propofol reduced reactive oxygen
species-induced lipid peroxidation and attenuated
ischaemia/reperfusion injury in isolated rat hearts in a
dose-dependent manner and can prevent hydrogen
peroxide-mediated exacerbation of tumor necrosis factor
(TNF)-a cellular toxicity [40], which might be a
mechanism whereby it attenuates hydrogen peroxide-
induced cardiac dysfunction. More recently, it has also
been shown that propofol post-conditioning confers
protection against myocardial as well as cerebral
ischaemia/reperfusion injury, probably through main-
taining the activity of the prosurvival PI3K/Akt pathway
[40,41]. Currently, however, there is not enough
evidence to definitively support the use of any particular
anaesthetic regime for cardioprotection in patients.
Nitrous oxide
The administration of nitrous oxide was associated with
increased long-term risk ofmyocardial infarction (1.3% vs
0.7%; adjusted P = 0.19), but not of death or stroke in
patients enrolled in the ENIGMA-1 trial [42]. Nitrous
oxide inhibits methionine synthetase, which mediates an
increase in homocysteine, which is an independent risk
factor for coronary artery and cerebral vascular disease.
Page 4 of 8
(page number not for citation purposes)
F1000Prime Reports 2013, 5:7 http://f1000.com/prime/reports/m/5/7
Increases in homocysteine have been found to cause
endothelial dysfunction, impair myocardial substrate
utilization, and enhance platelet aggregation. In a
substudy of ENIGMA-I, 394 unselected patients had
homocysteine measured preoperatively and on the first
postoperative day, which showed that a deficiency of
folate or B vitamins increased the incidence of hyperho-
mocysteinemia four-fold. Hyperhomocysteinemia was
associated with a doubling of the rate of major
complications. However, the longer-term results of the
original ENIGMA-I trial found that patients exposed to
nitrous oxide had an increased incidence of myocardial
infarction, in a mean follow-up period of 3.5 years after a
nitrous oxide-based general anaesthetic [43]. Conse-
quently, the routine use of nitrous oxide in patients
undergoing major surgery should be questioned.
Dexmedetomidine
Dexmedetomidine is a highly selective alpha-2 agonist
that provides sedation and analgesia without respiratory
depression. It activates pro-survival kinases and attenu-
ates ischaemia and hypoxic injury, including cardiopro-
tection [44], neuroprotection [45], and renoprotection
[46]. Concurrent infusion during surgery reduces anaes-
thetic consumption by 20-50% [47] and produces a
moderate decrease in heart rate and blood pressure that
may be advantageous in ischaemic heart disease by
improving oxygen supply/demand balance [48].
Thoracic epidural analgesia
Good pain control is an extremely important facet of the
anaesthetic technique, as it decreases stress hormone
production, sympathetic tone and myocardial oxygen
consumption. Thoracic epidural analgesia had been
thought to provide cardioprotective effects in patients
undergoing noncardiac surgery in several small studies
but this has not been borne out in meta-analysis [49] or
in the MASTER trial [50], where the only benefit was a
reduction in postoperative respiratory complications.
Blood glucose and blood pressure interventions
Diabetes mellitus is strongly associated with cardiovas-
cular disease, autonomic neuropathy and resistance to
preconditioning. Drugs like the glucose-lowering drug
glibenclamide also inhibit preconditioning. Interest-
ingly, however, a recent retrospective cohort study of
32,834 patients with known cardiac disease, of whom
28% had diabetes, found similar all-cause 30-day
mortality after noncardiac surgery [42]. None of the
glucose-lowering drug classes were associated with
perioperative mortality in elderly cardiac patients but
use of angiotensin-converting-enzyme (ACE) inhibitor
or angiotensin receptor blockers, beta-blockers, or
statins in the 100 days before surgery were associated
with lower 30-day mortality [51]. When the vogue for
aggressive use of insulin for tight perioperative glucose
control based on initial observational studies in the
intensive care unit setting was later investigated in
proper randomised trials, it was found to actually cause
higher mortality. Although it is prudent to avoid
hyperglycaemia, such aggressive treatment is no longer
recommended [52].
As with aspirin and statins, there is strong evidence that
long-term ACE inhibition yields significant cardiovascu-
lar protective effects. Traditionally it was common to
discontinue ACE inhibitors preoperatively because of an
association with intraoperative hypotension. However, a
recent large prospective study investigating postoperative
cardiovascular outcomes in patients with different
patterns of perioperative ACE inhibitor/angiotensin
receptor blockers use found that, although there was
no change in 30-day in-hospital mortality, withdrawal of
an ACE inhibitor was associated with an increased
number of cardiovascular events, mainly congestive
heart failure and postoperative myocardial infarction
[53]. Such high-level evidence suggests that ACE
inhibitor therapy should be continued if possible,
particularly considering that blood pressure changes
during surgery are easily attenuated with vasopressors
such as phenylephrine.
Conclusion
There is no “magic bullet” for the prevention of
perioperative cardiovascular morbidity and mortality.
However, an appropriate strategy is to identify those at
risk as early as possible and intervene, if needed, with
consideration of the urgency and nature of surgery. The
risk and benefit of surgery should also be seriously
considered in the context of less invasive alternatives if
possible (e.g. endovascular repair for aortic aneurysect-
omy). Current evidence strongly supports the use of
aspirin and statins. Beta blockade may be beneficial in
higher-risk groups but needs to be titrated to effect.
Chronic cardiovascular therapy including ACE inhibitor/
angiotensin receptor blockers should be maintained
and there is no need for tight blood glucose control in
diabetes. While certain volatile anaesthetics and opioids
showpromising effects inmitigating ischaemia/reperfusion
injury, large prospective randomized trials are still needed
to determine their clinical potential.
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